[新聞] TRXC 通過 FDA 了

原文標題： Asensus Surgical (TRXC) Announces FDA Clearance in General Surgery 原文連結：https://bit.ly/3q9VDlV 發布時間：March 3, 2021 6:55 AM EST 原文內容： Asensus Surgical, Inc. (formerly TransEnterix, Inc.) (NYSE American: TRXC) , a medical device company that is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery™, today announced the Company has received an additional FDA clearance for the Senhance Surgical System which allows for indication expansion in general surgery in the United States. Asensus Surgical's technology platform, Senhance® Surgical System, is the first of its kind digital laparoscopic platform that leverages augmented intelligence to provide unmatched performance and patient outcomes through machine learning. Senhance goes beyond the typical surgical robotic systems, providing surgical assurance through haptic feedback, eye-tracking camera control, and 3D visualization, and is the first platform to offer 3 mm instruments (the smallest instrument available in the world on a robotic surgical platform). “The expansion into general surgery for the Senhance Surgical System is a major milestone for the growth and clinical applicability of our technology,” said Anthony Fernando, Asensus Surgical President and CEO. “General surgery is, by far, the largest area of manual laparoscopy which can benefit from the precision and insight of Performance-Guided Surgery. The indication expansion allows Senhance to be used in many high-value, complex reconstructive surgeries such as those used to treat reflux and obesity. Including previous indications granted, the Senhance Surgical System can now be utilized in over 2.7 million general surgical procedures performed in the US annually." “Many of the procedures we perform in general surgery require complex reconstruction throughout a wide surgical field,” said Dr. Sabino Zani, Assistant Professor of Surgery at Duke University and an investigator in the clinical studies submitted for indication expansion. “Senhance can now be seen as a widely applicable tool for general surgeons across the broad range of procedures that may be performed from deep in the pelvis to the upper abdomen.” Senhance US Indication for Use The Senhance Surgical System is intended to assist in the accurate control of laparoscopic instruments for visualization and endoscopic manipulation of tissue including grasping, cutting, blunt and sharp dissection, approximation, ligation, electrocautery, suturing, mobilization, and retraction. The Senhance Surgical System is intended for use in general laparoscopic surgical procedures and laparoscopic gynecological surgery. The system is indicated for adult use. It is intended for use by trained physicians in an operating room environment in accordance with the instructions for use. 心得/評論： ※必需填寫滿20字 前陣子的飆股,雖然二月有滿滿的預期會通過FDA 但大漲大跌之下還是賣了一點 部位.這陣子的回調原本希望回到3.5再加倉,這下看來沒機會了.. ----------------------------------發文提醒------------------------------- 1.發文前請先詳閱[新聞]分類發文規範，未依規範發文將受處份。 2.連結過長請善用 https://bit.ly/ 縮網址，連結能不能點擊者板規1-2-2處份。 3.心得/評論請盡量充實，*[m心得過短或濫竽充數將會以1-2-3&一行文規範水桶處份 4.發文請依照格式文章標明段落，不符合格式者依4-1刪文處分。 ------------------ 以上注意事項請勿刪除 違者4-1 刪文處分----------------- -- ※ 發信站: 批踢踢實業坊(ptt.cc), 來自: 59.127.164.31 (臺灣) ※ 文章網址: https://www.ptt.cc/bbs/Stock/M.1614775792.A.1BB.html